Humog-75 HP

Pharmaceutical form Package № Dose strength
lyophilisate for solution for injection №1 75 IU

Manufacturer:Bharat Sirams End Vaksins Limited

Human menopausal gonadotropin, highly purified


In women:
- Anovulation (including polycystic ovarian syndrome).
- Monitored ovarian hyperstimulation, including for multiple follicle development induction during assisted reproductive treatments (for example in vitro fertilization/embryo transfer(IVF/ET) , intra cytoplasmic sperm injection (ICSI)
In men:
- spermatogenesis failure caused by hypothalamic amenorrhea


Active ingredients: 1 vial contains highly purified menotropin equivalent follicle stimulating hormone activity (FSH) and 75 IU and luteinizing hormone (LH) 75 in the ratio 1: 1; Excipients: mannitol (E 421), saccharose, double batching wayer-free sodium phosphate, sodium ascorbate, phosphoric acid (reconstituted), sodium hydroxide (reconstituted). Solvent: sodium chloride for injection 0.9%.


The medicine active ingredient is a highly purified human menopausal gonadotropin. The medicine contains FSH and LH, produced by the human basal gland by 75 in a ratio of 1: 1. The active ingredient was prepared from women, in postmenopausal period, urina. Menopausal gonadotropin produces follicle-stimulating effect. It increases concentration of sex hormones in plasma. It causes estrogen concentration increasing in women blood and stimulates ovarian growth, follicle maturating in them and ovulation; causes endometrium proliferation. It stimulates spermatogenesis in men (due to protein synthesis, connecting androgens in the seminiferous tubules and Sertoli cells, activation). It enhances steroid hormones production by the sexual glands. Efficiency is mainly associated with FSH action.